THIS ANNOUNCEMENT, INCLUDING THE APPENDIX AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR IMMEDIATE RELEASE.

15 June 2022

Rockhopper Exploration plc
("Rockhopper" or the "Company")

Proposed Capital Raise

Proposed equity raise of approximately US$4.5 million (approximately £3.7 million) by way of a Placing and a proposed Subscription

and

Open Offer of up to approximately US$5 million (approximately £4.1 million)

The Company today announces its intention to raise approximately US$4.5 million (approximately £3.7 million), before expenses, by way of a Placing and a proposed Subscription, in each case at an issue price of 7 pence per Unit (the "Issue Price"). Each Unit being offered comprises one New Ordinary Share and, for every two New Ordinary Shares subscribed for, one Warrant. Each Warrant gives the holder the right to subscribe for one new Ordinary Share at a price of 9 pence per Ordinary Share (the "Strike Price") at any time from the issue of the Warrants up to (and including) 5.00 p.m. on 31 December 2023 (the "Warrant Exercise Period"). The Issue Price represents a discount of approximately 12.5 per cent. to the Closing Price of 8 pence per Existing Ordinary Share on 14 June 2022 (being the latest practicable date prior to the release of this announcement (together with the Appendix, the "Announcement")).

In addition, the Company is seeking to raise up to approximately US$5 million (£4.1million) through an Open Offer (together with the Placing and Subscription, the "Capital Raising") pursuant to which Units will be offered to existing Shareholders at the Issue Price. If the Resolutions to (i) allot shares (or rights to subscribe for or to convert any security into shares) and, (ii) disapply pre-emption rights are not approved by Shareholders at the 2022 Annual General Meeting, the Open Offer will not complete.

The proceeds from the proposed Placing and Subscription are expected to provide the Company with sufficient working capital to the end of June 2023. Any additional proceeds from the Open Offer would provide working capital beyond this period depending on the amount raised.

Subject to demand from potential investors to participate in the Placing and the existing authorities granted at the 2021 Annual General Meeting, the Directors have reserved flexibility to increase the size of the Placing. The Placing is being conducted through an accelerated bookbuild process (the "Bookbuild"), which will be launched immediately following this Announcement and will be made available to new and existing eligible institutional investors. The Placing is subject to the terms and conditions set out in the Appendix to this Announcement. Canaccord Genuity Limited ("Canaccord") and Peel Hunt LLP ("Peel Hunt") are together acting as joint bookrunners (the "Joint Bookrunners") in relation to the Placing. The Bookbuild is expected to remain open until 9 p.m. on 15 June 2022, however this remains subject to change at the discretion of the Joint Bookrunners (in consultation with the Company).

The Directors, have indicated an intention to subscribe for Units, pursuant to the Subscription at the Issue Price, which would raise gross proceeds of approximately US$190,000 in aggregate.

The Company considers it important that existing Shareholders who are not able to take part in the Placing or the Subscription are given an opportunity to participate in the Capital Raising. The Company will therefore provide Qualifying Shareholders with the opportunity to subscribe for Units, comprising of Open Offer Shares and Warrants, at the Issue Price pursuant to an Open Offer, to raise gross proceeds of up to approximately US$5 million (approximately £4.1 million) if fully taken-up. The Open Offer will include an excess application facility to enable Qualifying Shareholders to apply for additional Units in excess of their entitlements under the Open Offer. Completion of the Open Offer will be conditional upon, among other things, the approval by the Company's Shareholders of resolutions to grant the Directors of the Company authority to (i) allot shares or rights to subscribe for or to convert any security into shares, and (ii) disapply pre-emption rights (the "Resolutions") at the annual general meeting of the Company expected to be held on 28 June 2022 (the "2022 Annual General Meeting").

If the Resolutions are not approved by Shareholders at the 2022 Annual General Meeting, the Open Offer will not complete. The Directors consider the terms of the Capital Raising (described in more detail below) to be in the best interests of Shareholders and of the Company as a whole. Accordingly, the Directors unanimously recommend that Shareholders vote in favour of the Resolutions at the 2022 Annual General Meeting to be held on 28 June 2022.

Details on how to vote at the 2022 Annual General Meeting are set out in the Notice of Annual General Meeting published by the Company on 6 June 2022, which can be found on the Company's website (www.rockhopperexploration.co.uk).

Sam Moody, CEO of Rockhopper Exploration plc said:

"The strategy and focus of the Board is to maximise the likelihood of project sanction at Sea Lion. At current oil prices, the Board believes the potential value creation to Shareholders by sanctioning Sea Lion, a 500 million barrel oil field with significant upside, is highly material. In order to pursue this strategy, the Company requires sufficient funding to pay its reduced corporate costs, licence fees, costs associated with the completion of the Navitas Transaction and various other costs not covered under the Navitas loan agreement. The proposed equity raise helps us achieve that while we focus on the ultimate prize of Sea Lion project sanction."

Capital Raising - Further Information

·      For the avoidance of doubt, the Capital Raising is not being underwritten by the Joint Bookrunners or any other party, whether as to settlement risk or otherwise.

·      The Company intends to issue the Placing Units (including both the Placing Shares and the Placing Warrants) by way of a non-pre-emptive cashbox placing.

·      The timing for the close of the Bookbuild shall be at the discretion of the Joint Bookrunners, in consultation with the Company.

·      Allocation of the Placing Units shall be determined by the Company in consultation with the Joint Bookrunners.

·      At the Company's 2021 Annual General Meeting held on 29 June 2021, the Directors were granted authorities to allot shares or rights to subscribe for or to convert any security into shares under section 551 of the Act. This authority is sufficient to enable the Company to allot and issue the full amount of Placing Units pursuant to the Placing and the Subscription Units pursuant to the Subscription. The Company is scheduled to hold its 2022 Annual General Meeting on 28 June 2022, at which the Company is proposing Resolutions to grant the Directors authority to (i) allot shares or rights to subscribe for or to convert any security into shares under section 551 of the Act, and (ii) disapply pre-emption rights under section 570 of the Act. If passed, these Resolutions would be sufficient to enable the Company to allot and issue the full amount of Open Offer Units to be issued pursuant to the Open Offer. If the Resolutions are not approved by Shareholders at the 2022 Annual General Meeting, the Open Offer will not complete.

·      The Placing and the proposed Subscription are conditional upon:

o  First Admission becoming effective by not later than 8.00 a.m. on 20 June 2022 or such later date as may be agreed by the Company and the Joint Bookrunners; and

o  the Placing and Open Offer Agreement becoming unconditional with respect to First Admission and not having been terminated by the Joint Bookrunners in accordance with its terms.

·      The Open Offer is further conditional upon, among other things:

o  the Resolutions being passed by Shareholders at the 2022 Annual General Meeting; and

o  Second Admission becoming effective.

·      The Placing and the proposed Subscription are not conditional upon completion of the Open Offer. It is therefore possible that the Placing and the proposed Subscription proceed, but the Open Offer does not.

·      The Appendix to this Announcement (which forms part of this Announcement) contains the detailed terms and conditions of the Placing.

·      The Company expects to publish a circular (the "Circular") in connection with the Open Offer following the closure of the Bookbuild. Full details, including terms and conditions, of the Open Offer will be included in the Circular. Please note that subscription for Units under the Placing will not carry any entitlement to subscribe for New Ordinary Shares or Warrants under the Open Offer.

·      Applications will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. It is expected that First Admission will become effective and that dealings in respect of the Placing Shares and the Subscription Shares will commence at 8.00 a.m. on 20 June 2022.

·      The Warrants will not be admitted to trading on AIM or on any other stock exchange. The Warrants are capable of being settled in CREST. It is currently intended that settlement of Warrants via CREST will be on the same timetable as settlement of the Placing Shares and Subscription Shares or the Open Offer Shares, as applicable. Warrant certificates in respect of the Warrants issued pursuant to the Placing will be issued to certificated holders only and are currently expected to be dispatched within 14 days of First Admission.

Current Trading and Prospects

The Company's results for the twelve months ended 31 December 2021 were released on 30 May 2022. A copy of these results can be found at www.rockhopperexploration.co.uk.

As noted in the Company's results for the twelve months ended 31 December 2021, as at 30 April 2022, the Group had (unaudited) cash resources of approximately US$3.4 million. There have been no material changes to the performance of the Group since the publication of these results.

Recent Events

In April 2022, the Company, Harbour Energy and Navitas announced that they had signed legally binding definitive documentation in relation to Harbour Energy exiting and Navitas entering the North Falkland Basin (the "Navitas Transaction").

The details of the Navitas Transaction (including the proposed Navitas Loans and the key conditions to the Navitas Transaction) are set out, along with the future plans for Sea Lion, in the RNS announcement dated 19 April 2022.

Background to and reasons for the Capital Raising

The strategy and focus of the Board is to maximise the likelihood of project sanction at Sea Lion. At current oil prices, the Board believes the potential value creation to Shareholders by sanctioning Sea Lion, a 500 million barrel oil field with significant upside, is highly material.

In order to pursue this strategy, the Company requires sufficient funding to pay its reduced corporate costs, licence fees, costs associated with the completion of Navitas Transaction and various other costs not covered under the Navitas loan agreement, including all costs relating to the South Falkland licences. The Navitas Loans only become available on completion of the Navitas Transaction, which requires (among other things) UK Secretary of State approval and could take a number of months.

As set out in the Company's 2021 Annual Report, the Company had cash resources of US$4.8 million as at 31 December 2021. As at 30 April 2022, the Company had (unaudited) cash resources of approximately US$3.4 million. The Company has not raised funds from Shareholders since 2011.

The Company estimates that additional funding of a minimum of US$4.5 million (approximately £3.7 million) would be sufficient to run the Company for the next 12 months, by which time the Company is hopeful that a decision will have been issued by the panel in relation to the Ombrina Mare Arbitration. Once that decision is known, the Company will be in a position to better determine its future funding requirements. See section on 'Rockhopper's Italian Assets' below for further details.

Background to Rockhopper and the Sea Lion Project

The Company is an AIM-quoted oil and gas exploration and production company based in the UK with key interests in the Falkland Islands. It was established in 2004 and admitted to trading on AIM in August 2005. Rockhopper's current market value is approximately £36.6million.

Since 2004, the Company has built a portfolio of licences in the North Falkland Basin, containing Sea Lion and satellite discoveries. The Company discovered Sea Lion in May 2010 and went on to appraise and flow-test the field during the remainder of 2010 and 2011, as operator with a 100 per cent. working interest. Sea Lion is accordingly well appraised and has been the subject of many years of sub-surface, facilities engineering and pre-development work.

Sea Lion has been independently audited on a number of occasions, including by ERC Equipoise Limited ("ERCE") in 2016, to contain in excess of 500 mmbbls of recoverable oil on a 2C Contingent Resource basis, and 900 mmbbls of recoverable oil on a 3C Contingent Resource basis. For comparative purposes, based on this independent assessment, Sea Lion would be one of the largest undeveloped oil fields in the UK North Sea if it were located on the UK continental shelf.

The Company notes that, in May 2022, Navitas separately commissioned Netherland Sewell & Associates, Inc. (a third party mineral expert) to conduct its own independent audit of the contingent and prospective resources of Sea Lion, which followed a different approach to the ERCE 2016 audit. The results of this audit indicate higher contingent and prospective resources than concluded by ERCE in its 2016 audit.

In 2012, the Company farmed down 60 per cent. and operatorship of its licence interests in the North Falkland Basin, including Sea Lion, to Premier Oil.

From 2012 to 2021, Premier Oil undertook various pre-development activities including front end engineering and design and other studies with the aim of developing the field. Premier Oil submitted an 'Environmental Impact Assessment' and draft 'Field Development Plan' to FIG. The 'Environmental Impact Assessment' was accepted by FIG in 2020. Furthermore, significant efforts were historically expended to secure financing for the project. The Company estimates the total cost of the work conducted to date to be in excess of US$300 million.

In March 2021, Premier Oil was acquired by Chrysaor Holdings Limited to create Harbour Energy. As part of the acquisition, Harbour Energy conducted a strategic review of Premier Oil's asset portfolio and concluded in September 2021 that Sea Lion, amongst other development assets it was acquiring, was not a strategic fit for the enlarged business. As a result, Harbour Energy decided to exit its interests in the Falkland Islands.

About Navitas Petroleum

Navitas is a publicly traded (TASE:NVPT.L) North America focused oil and gas exploration and production partnership. It has a strong track record in equity and debt capital markets, having raised approximately US$1.4 billion since 2017. Its forecast production for 2022 is over 5,000 boepd.

Navitas has an established asset portfolio, including conventional onshore production (Neches field and Denbury assets), robust offshore production (Buckskin project), development stage assets with a clear path to first production (Shenandoah project) and high-impact exploration prospects (Block 7, offshore Canada).

The recent FID for the Shenandoah project is expected to be transformational for Navitas. In August 2021, Navitas and its partners in the Shenandoah project raised financing in excess of US$900 million. Furthermore, in 2021 Navitas raised over US$300 million in corporate debt and equity transactions.

Excluding Sea Lion, Navitas has over 260 million barrels of 2P/2C resources and an existing work programme in place to increase production to approximately 60,000 bbls/d (net) by 2025. Navitas' 2022 EBITDA is estimated to be in the region of US$60 million and is projected to increase to approximately US$800 million by 2025.

Navitas boasts an experienced team with a track record of success in offshore developments. Navitas' Chairman is Mr Gideon Tadmor, one of the founders and major drivers behind the success of the Eastern Mediterranean oil and gas sector. As the CEO and Chairman of Delek Group's upstream companies, Mr Tadmor led the efforts of world class discoveries such as the 11 TCF Tamar field and the 22 TCF Leviathan field.

The information in this section relating to Navitas has been sourced from Navitas. Navitas is listed on the Tel Aviv Stock Exchange. This information has not been independently verified by the Company or the Joint Bookrunners.

Rockhopper's Other Falkland Licence Interests

In addition to the Licences in the North Falkland Basin, the Company holds a 100 per cent. interest and is the operator of licences PL011, PL012 and PL014 in the South and East of the Falklands.

The Company considers these licences to be potentially prospective for gas resources. In particular, licence PL011 is adjacent to a large gas-condensate discovery made by Borders & Southern Limited in April 2012.

Rockhopper's Italian Assets

The Company commenced international arbitration proceedings against the Republic of Italy in relation to the Ombrina Mare field in March 2017. The Company believes that Republic of Italy breached the Energy Charter Treaty ("ECT") following the decision in February 2016 by the Ministry of Economic Development not to award the Company a Production Concession covering the Ombrina Mare field. The hearing took place in early February 2019 in Paris. In June 2019, the tribunal rejected Italy's request for the suspension of the arbitration and Italy's related intra-EU jurisdictional objections.

The proceedings related to the Ombrina Mare Arbitration were declared closed in accordance with Rule 38(1) of the ICSID Arbitration Rules on 25 April 2022.

Under the ICSID Arbitration Rules, the tribunal has 120 days after closing to issue its award, extendable by 60 days (Rule 46). Any award issued by the tribunal must therefore be issued by 23 August 2022 or, if extended, 22 October 2022.

The Company continues to believe it has strong prospects of recovering very significant monetary damages (on the basis of lost profits) as a result of the Republic of Italy's breaches of the ECT. All of the Company's costs associated with the arbitration to date have been funded on a non-recourse ('no win-no fee') basis from a specialist arbitration funder. Should damages be awarded, the funder will receive a proportion of the damages based on funds spent and the size of any award. There can be no certainty as to the amount, if any, that will be awarded from the Ombrina Mare Arbitration.

In addition, the Company holds legacy interests in various Italian licences following its acquisition of Mediterranean Oil and Gas plc in 2014. Many of these interests will require abandonment at some point in the future. As disclosed in the Company's 2021 Annual Report, the total estimated cost of the eventual field abandonment and site restoration was US$14.2 million. Currently no material costs in relation to these activities are envisaged before the end of 2024. To the extent that activities are planned before the end of 2024 they can be funded from existing resources.

Other

The Company is also considering issuing share options to an experienced and successful oil and gas development project manager who would oversee the Sea Lion development for the Navitas / Rockhopper joint venture as a part of that individual's overall remuneration package. Further details will be provided in due course.

Use of Proceeds

It is currently expected that the gross proceeds of the Placing, expected to be approximately US$4.5 million (approximately £3.7 million), will provide sufficient capital to support the Company in achieving:

(a)      completion of the Navitas Transaction;

(b)      licence extension in the North Falkland Basin; and

(c)      outcome of the Ombrina Mare arbitration.

The Company will issue Warrants to those participating in the Capital Raising that enable the purchase of additional Ordinary Shares at the Strike Price, being a premium to the Issue Price.

Warrants are only likely to be exercised once the Company's share price has increased substantially from the Issue Price, so the Shareholder will see appreciation in the value of the new Ordinary Shares they received from the Capital Raising if Warrants are exercised.

Importance of Vote at the 2022 Annual General Meeting

The Resolutions being proposed at the 2022 Annual General Meeting are, (i) in respect of the resolution relating to the granting of authority to Directors to allot shares (or rights to subscribe for or to convert any security into shares), an ordinary resolution which, to be passed, will require the support of a simple majority of the total voting rights of Shareholders who (being entitled to do so) vote on such resolution at the 2022 Annual General Meeting, and (ii) in respect of the resolution relating to the granting of authority to Directors to disapply pre-emption rights, a special resolution which, to be passed, will require the support of a majority of not less than 75 per cent. of the total voting rights of Shareholders who (being entitled to do so) vote on such resolution at the 2022 Annual General Meeting. The Open Offer is conditional, inter alia, on the passing of the Resolutions.

In the event that the Resolutions are not passed at the 2022 Annual General Meeting, the Company will not be able to proceed with the Open Offer and Shareholders will not get the opportunity to participate in the Open Offer, with the result that the anticipated net proceeds of the Open Offer will not become available to the Company.

The Directors consider that the scenario described above would not be in the best interests of the Company or its Shareholders as a whole and that any alternative financing, if available, could be on less favourable terms and could lead to more substantial dilution for Shareholders than would be the case under the proposed Open Offer. Accordingly, the Directors believe that the passing of the Resolutions are in the best interests of Shareholders and recommend that Shareholders vote in favour of the Resolutions at the 2022 Annual General Meeting.

Risk Factors

Please see below certain key risk factors related to the business of the Group. Please see the Annual Report and Accounts issued on 6 June 2022 for details of other risk factors.

1.         The Group's financial position will be materially and adversely affected if the Capital Raising does not proceed

If the Capital Raising does not proceed, the Company would have insufficient working capital to execute its intended strategy and would need to seek alternative sources of funding in the short to medium term, which may or may not be forthcoming. In these circumstances, there can be no certainty that the Group would be able to secure additional financing on commercially acceptable terms or at all.

2.         The Navitas Transaction may not complete

Completion of the Navitas Transaction is subject to a number of conditions precedent, including, but not limited to, obtaining the FIG Consents (which are further described above). There is no guarantee that the aforementioned FIG Consents and other conditions precedent will be satisfied or, where appropriate, waived. In the event that some, or all, of the conditions precedent are not satisfied (or waived), the Navitas Transaction may not complete. In these circumstances, there may be a number of materially adverse consequences for the Company in respect of its operations and prospects generally. These include the possibility that FIG does not grant an extension of the Licences and/or that the Company loses its Licences in the North Falkland Basin.

In addition, if the Navitas Transaction does not complete, Harbour Energy may exercise its rights to wind down all operations in respect of the Licences (and the Company is required to bear 40 per cent. of such costs). In such event, the Company has the right to acquire Harbour Energy's Licence interests for US$1. Regardless of whether the Company exercises such option, unless otherwise agreed by Harbour Energy and the Company, Harbour will wind down operations, including the decommissioning of the temporary dock facility. The Company believes that its 40 per cent. share in the costs of removing the temporary dock facility could be in the region of approximately US$4 million.

3.         Sufficient funding required to develop the Sea Lion project may not be obtained

Even if the Navitas Transaction does complete (see above), it is possible that Sea Lion will not be developed. Significant funds will be required in the future to complete the development of the Sea Lion project and there is no guarantee that the Company and Navitas (nor any other additional project partner who may be incorporated in the future into the Sea Lion project) would each be able to raise the requisite funds to develop the Sea Lion project. Furthermore, there can be no assurance that any such funds raised by either the Company or Navitas would be available on favourable terms. If the Company and/or Navitas are unable to obtain additional financing as required, they may potentially fail to meet their respective financial and operational obligations. As a result, they may not be able to develop the Sea Lion project or may need to reduce the scope of their operations in connection with the Sea Lion project, which could have a material adverse effect on the Group's business, results of operations and financial condition.

4.         The Company and Navitas may not be able to agree a development plan

There is a risk that the Company and Navitas may not be able to agree a development plan. In addition, in the event that the Company does not approve the development of the Sea Lion field, Navitas may have the right to propose and carry out the development as an exclusive operation. In such event, the Company may be deemed to have relinquished its rights in the development, which could have a material adverse effect on the Group's business, results of operations and financial condition.

5.         The sovereignty of the Falkland Islands is disputed and as there has never been an oil or gas development in the Falklands there is uncertainty as to the application of the fiscal regime and regulatory requirements

There is a longstanding and ongoing dispute between the Argentinian Government and the UK Government over ownership and control of the Falkland Islands. Whilst open aggression is not expected, certain service providers and financial institutions may choose not to provide services for fear of the impact an association may have on their business in Argentina, which could have a material adverse effect on the Group's business, results of operations and financial condition. Furthermore, as there has never been an oil development carried out in the Falklands, there is uncertainty as to the fiscal regime and regulatory requirements imposed on oil and gas companies operating in the Falkland Islands, as this legislation has never been applied and tested.

IMPORTANT NOTICES

The information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under Article 7 of the Market Abuse Regulation (EU) No. 596/2014 (as amended) as it forms part of the domestic law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (as amended). Upon the publication of this Announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

This Announcement contains (or may contain) certain forward-looking statements with respect to certain of the Company's plans and its current goals and expectations relating to its future financial condition and performance and which involve a number of risks and uncertainties. The Company cautions readers that no forward-looking statement is a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statements. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements sometimes use words such as "aim", "anticipate", "target", "expect", "estimate", "intend", "plan", "goal", "believe", or other words of similar meaning. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances, including, but not limited to, economic and business conditions, the effects of continued volatility in credit markets, market-related risks such as changes in the price of commodities or changes in interest rates and foreign exchange rates, the policies and actions of governmental and regulatory authorities, changes in legislation, the further development of standards and interpretations under International Financial Reporting Standards ("IFRS") applicable to past, current and future periods, evolving practices with regard to the interpretation and application of standards under IFRS, the outcome of pending and future litigation or regulatory investigations, the success of future explorations, acquisitions and other strategic transactions and the impact of competition. A number of these factors are beyond the Company's control. As a result, the Company's actual future results may differ materially from the plans, goals, and expectations set forth in the Company's forward-looking statements. You should not place undue reliance on forward-looking statements. Any forward-looking statements made in this Announcement by or on behalf of the Company speak only as of the date they are made. Except as required by the FCA, the London Stock Exchange or applicable law, the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this Announcement to reflect any changes in the Company's expectations with regard thereto or any changes in events, conditions or circumstances on which any such statement is based.

This Announcement is for information purposes only and shall not constitute an offer to buy, sell, issue, or subscribe for, or the solicitation of an offer to buy, sell, issue, or subscribe for any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unauthorised or unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any failure to comply with these restrictions may constitute a violation of the securities law of any such jurisdiction.

This Announcement is not an offer of securities for sale in or into the United States. The Units, New Ordinary Shares, Warrants and Open Offer Entitlements have not been and will not be registered under the US Securities Act 1933, as amended (the "Securities Act") or with any securities regulatory authority of any state or other jurisdiction of the United States and may not be offered, sold, delivered, transferred, or taken up, directly or indirectly, in or into the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. The Company does not intend to register any portion of the Capital Raising in the United States or to conduct an offering of securities in the United States.

This Announcement does not contain an offer or constitute any part of an offer to the public within the meaning of Sections 85 and 102B of the FSMA or otherwise. This Announcement is not an "approved prospectus" within the meaning of Section 85(7) of the FSMA and a copy of it has not been, and will not be, delivered to the FCA in accordance with the Prospectus Regulation Rules or delivered to any other authority which could be a competent authority for the purpose of the Prospectus Regulation (EU) 2017/1129 (the "EU Prospectus Regulation") or the UK version of Prospectus Regulation (EU) 2017/1129 as it forms part of retained EU law by virtue of the European Union (Withdrawal) Act 2018, as amended (the "UK Prospectus Regulation"). Its contents have not been examined or approved by the London Stock Exchange, nor has it been approved by an "authorised person" for the purposes of Section 21 of the FSMA. This Announcement is being distributed to persons in the United Kingdom only in circumstances in which section 21(1) of the FSMA does not apply.

This Announcement is directed only at: (a) persons in member states of the European Economic Area who are qualified investors within the meaning of article 2(e) of the EU Prospectus Regulation and (b) if in the United Kingdom, persons who (i) have professional experience in matters relating to investments who fall within the definition of "investment professionals" in article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or are high net worth companies, unincorporated associations or partnerships or trustees of high value trusts as described in article 49(2) of the Order, and (ii) are qualified investors as defined in article 2(e) of the UK Prospectus Regulation, and (c) otherwise, to persons to whom it may otherwise be lawful to communicate it (all such persons together being referenced to as "Relevant Persons"). Any investment in connection with the Placing will only be available to, and will only be engaged with, Relevant Persons. Any person who is not a Relevant Person should not act or rely on this Announcement or any of its contents.

This Announcement has been issued by and is the sole responsibility of the Company. No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by the Joint Bookrunners (apart from the responsibilities or liabilities that may be imposed by the FSMA or other regulatory regime established thereunder) or by any of their respective affiliates or agents as to, or in relation to, the accuracy or completeness of this Announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefor is expressly disclaimed. 

Canaccord Genuity Limited ("Canaccord"), which is authorised and regulated in the United Kingdom by the FCA, is acting as nominated adviser and joint bookrunner for the Company and for no-one else in connection with the Capital Raising, and Canaccord will not be responsible to anyone other than the Company for providing the protections afforded to its customers or for providing advice to any other person in relation to the Capital Raising or any other matter referred to herein.

Peel Hunt LLP ("Peel Hunt"), which is authorised and regulated in the United Kingdom by the FCA, is acting as joint bookrunner for the Company and for no-one else in connection with the Capital Raising, and Peel Hunt will not be responsible to anyone other than the Company for providing the protections afforded to its customers or for providing advice to any other person in relation to the Capital Raising or any other matter referred to herein.

The distribution of this Announcement and the offering of the Units in certain jurisdictions may be restricted by law. No action has been taken by the Company or the Joint Bookrunners that would permit an offering of such securities or possession or distribution of this Announcement or any other offering or publicity material relating to such securities in any jurisdiction where action for that purpose is required. Persons into whose possession this Announcement comes are required to inform themselves about, and to observe, such restrictions.

The Announcement does not constitute a recommendation concerning any investor's options with respect to the Placing. The Units to which this Announcement relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the Units should conduct their own due diligence, analysis and evaluation of the business and data described in this Announcement, including the Units. The pricing and value of securities can go down as well as up. Past performance is not a guide to future performance. The contents of this Announcement are not to be construed as financial, legal, business or tax advice. If you do not understand the contents of this Announcement you should consult an authorised financial adviser, legal adviser, business adviser or tax adviser for financial, legal, business or tax advice.

The information in this Announcement may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, dissemination, reproduction, or disclosure of this information in whole or in part is unauthorised. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

Neither the content of the Company's website nor any website accessible by hyperlinks on the Company's website is incorporated in, or forms part of, this Announcement.

Information to Distributors

Solely for the purposes of the product governance requirements contained within: (a) the UK's implementation of EU Directive 2014/65/EU on markets in financial instruments, as amended ("UK MiFID II"); and (b) the UK's implementation of Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing UK MiFID II, and in particular Chapter 3 of the Product Intervention and Product Governance Sourcebook of the FCA (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Units have been subject to a product approval process, which has determined that such Units are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in UK MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by UK MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, distributors (such term to have the same meaning as in the MiFID II Product Governance Requirements) should note that: the price of the Units may decline and investors could lose all or part of their investment; the Units offer no guaranteed income and no capital protection; and an investment in the Units is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Capital Raising. Furthermore, it is noted that, notwithstanding the Target Market Assessment, the Joint Bookrunners will only procure investors (pursuant to the Placing) who meet the criteria of professional clients and eligible counterparties. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of UK MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Units. Each distributor is responsible for undertaking its own target market assessment in respect of the Units and determining appropriate distribution channels.

The Joint Bookrunners may, in accordance with applicable laws and regulations, engage in transactions in relation to the New Ordinary Shares and/or related instruments for its own account and, except as required by applicable laws or regulations, does not propose to make any public disclosure in relation to such transactions.

EXPECTED TIMETABLE OF PRINCIPAL EVENTS OF THE PLACING AND THE PROPOSED SUBSCRIPTION

Each of the times and dates in the table above is indicative only and may be subject to change. If any of the details contained in the timetable above should change, the revised times and dates will be notified by means of an announcement through a Regulatory Information Service. References to times are to London time unless stated otherwise. The timetable above assumes that the Placing and Open Offer Agreement becomes unconditional in all respects with respect to First Admission and is not terminated in accordance with its terms by the Joint Bookrunners. Further details on the timetable in relation to the Open Offer will be included in the Circular.

FURTHER DETAILS OF THE CAPITAL RAISING

Details of the Warrants

As detailed above, the Company has agreed to issue Warrants to investors in the Placing on the basis of one Warrant for every two Placing Shares subscribed for under the Placing, or for every two Subscription Shares subscribed for under the Subscription. Entitlements to Warrants shall be rounded down and fractional entitlements shall be disregarded. Each Warrant will have the right to subscribe for one new Ordinary Share. The Warrants are exercisable at a price of 9 pence per Ordinary Share during the Warrant Exercise Period. The issue and validity of the Warrants in the Placing is not conditional on the passing of the Resolutions at the 2022 Annual General Meeting.

Participation in the Open Offer will also entitle the subscriber to Warrants on the same basis as in the Placing.

None of the Warrants will be admitted to trading on AIM or any other stock exchange. The other key terms and conditions of the Warrants are set out below:

a)   Subscription rights: Each Warrant issued will confer on the holder the right to subscribe for one new Ordinary Share at an exercise price of9 pence per Ordinary Share by notice to the Company during the Warrant Exercise Period.

b)   Warrant Exercise Period: The exercise period for a Warrant is the period from the date of issue of the Warrant up to (and including) 5.00 p.m. on 31 December 2023 (unless terminated earlier in accordance with the terms of the Warrants).

c)   Adjustment to subscription rights: The subscription rights conferred by the Warrants and/or the exercise price of the Warrants shall be adjusted by the Board in its sole discretion on the occurrence of certain events in relation to the Company, including:

i. a subdivision, consolidation or reclassification of the Ordinary Shares;

ii.          a reduction of capital or any other reduction in the number of Ordinary Shares in issue from time to time; or

iii.         an issue of Ordinary Shares by way of dividend or distribution or by way of capitalisation of profits or reserves,

 with the intention, in broad terms, that any such adjustment will leave the holder(s) of the Warrant(s) in a similar position to the position they were in immediately before the event giving rise to the adjustment.

d)   Transfer: The Warrants are, subject to certain conditions, freely transferable by the holders.

e)   Security: The Warrants are not secured.

f)    Modifications: The Company may amend the provisions of the instrument constituting the Warrants (the "Warrant Instrument") without the consent of the holders of the Warrants where such amendment is of a minor nature or to correct a manifest error. Otherwise no amendments or abrogations to the terms of the Warrant Instrument are permitted without the consent of holders of at least 75 per cent. of the Warrants in issue at the time.

g)   Administration: The Warrants are capable of being settled in CREST. It is currently intended that settlement of Warrants via CREST will be on the same timetable as settlement of (i) the Placing Shares, in the case of Warrants issued pursuant to the Placing, (ii) the Subscription Shares, in the case of Warrants issued pursuant to the Subscription, or (iii) the Open Offer Shares, in the case of Warrants issued pursuant to the Open Offer. Warrant certificates in respect of the Warrants issued pursuant to the Capital Raising will be issued to certificated holders only and are currently expected to be dispatched to Shareholders within 14 days of the issue of the Placing Shares, Subscription Shares or Open Offer Shares, as applicable.

Any Warrants remaining unexercised after the end of the Warrant Exercise Period shall automatically expire without compensation. Upon exercise of the Warrants, the underlying Ordinary Shares will be issued within 14 days. There are also provisions in the Warrant Instrument for meetings of the holders of Warrants.

The Open Offer

The Company considers it important that Shareholders who are not able to take part in the Placing and/or the Subscription have an opportunity to participate in the Capital Raising. The Company will therefore provide Qualifying Shareholders with the opportunity to subscribe for Units at the Issue Price pursuant to an Open Offer, to raise up to approximately US$5 million (approximately £4.1 million) if fully taken-up.

Subject to fulfilment of the conditions of the Open Offer, the Open Offer will provide Qualifying Shareholders with the opportunity to apply to acquire Open Offer Units at the Issue Price pro rata to their holdings of Existing Ordinary Shares against all Existing Ordinary Shares held by Qualifying Shareholders as at the Open Offer Record Date on the following basis:

1 Open Offer Unit for every 8 Existing Ordinary Shares held by Qualifying Shareholders

Each Open Offer Unit will comprise one Open Offer Share and, for every two Open Offer Shares subscribed for, one Warrant.

Further information on the Open Offer will be set out in the Circular.

Overseas Shareholders

Certain Overseas Shareholders may not be permitted to subscribe for Open Offer Shares pursuant to the Open Offer.

Definitions

Appendix I

TERMS AND CONDITIONS OF THE PLACING

IMPORTANT INFORMATION ON THE PLACING FOR INVITED PLACEES ONLY

MEMBERS OF THE PUBLIC ARE NOT ELIGIBLE TO TAKE PART IN THE PLACING (AS DEFINED BELOW). THIS ANNOUNCEMENT AND THE TERMS AND CONDITIONS SET OUT IN THIS APPENDIX (TOGETHER, THE "ANNOUNCEMENT") ARE FOR INFORMATION PURPOSES ONLY AND ARE DIRECTED ONLY AT PERSONS WHOSE ORDINARY ACTIVITIES INVOLVE THEM IN ACQUIRING, HOLDING, MANAGING AND DISPOSING OF INVESTMENTS (AS PRINCIPAL OR AGENT) FOR THE PURPOSES OF THEIR BUSINESS AND WHO HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS AND ARE: (A) IF IN A MEMBER STATE OF THE EUROPEAN ECONOMIC AREA (THE "EEA"), PERSONS WHO ARE QUALIFIED INVESTORS ("EU QUALIFIED INVESTORS") WITHIN THE MEANING OF ARTICLE 2(E) OF PROSPECTUS REGULATION (EU) 2017/1129 (THE "EU PROSPECTUS REGULATION"); (B) IF IN THE UNITED KINGDOM, PERSONS WHO (I) ARE "INVESTMENT PROFESSIONALS" SPECIFIED IN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (THE "ORDER") AND/OR (II) FALL WITHIN ARTICLE 49(2)(A) TO (D) OF THE ORDER (AND ONLY WHERE THE CONDITIONS CONTAINED IN THOSE ARTICLES HAVE BEEN, OR WILL AT THE RELEVANT TIME BE, SATISFIED) AND, IN EACH CASE, WHO ARE ALSO QUALIFIED INVESTORS (WITH PERSONS FALLING IN THIS PART (B) BEING "UK QUALIFIED INVESTORS" AND, TOGETHER WITH EU QUALIFIED INVESTORS, "QUALIFIED INVESTORS") WITHIN THE MEANING OF ARTICLE 2 OF THE EU PROSPECTUS REGULATION AS AMENDED AND TRANSPOSED INTO THE LAWS OF THE UNITED KINGDOM PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AND THE EUROPEAN UNION (WITHDRAWAL AGREEMENT) ACT 2020 (THE "UK PROSPECTUS REGULATION"); OR (C) PERSONS TO WHOM IT MAY OTHERWISE BE LAWFULLY COMMUNICATED (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS "RELEVANT PERSONS").

THIS ANNOUNCEMENT MUST NOT BE ACTED ON OR RELIED ON BY PERSONS WHO ARE NOT RELEVANT PERSONS. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO RELEVANT PERSONS AND WILL BE ENGAGED IN ONLY WITH RELEVANT PERSONS.

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA, SWITZERLAND, JAPAN, NEW ZEALAND OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT DOES NOT ITSELF CONSTITUTE AN OFFER FOR SALE OR SUBSCRIPTION OF ANY SECURITIES IN ROCKHOPPER EXPLORATIONPLC (THE "COMPANY").

THE SECURITIES REFERRED TO IN THIS ANNOUNCEMENT HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "US SECURITIES ACT"), OR UNDER THE SECURITIES LAWS OR WITH ANY SECURITIES REGULATORY AUTHORITY OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES, AND MAY NOT BE OFFERED, SOLD, TAKEN UP, RESOLD TRANSFERRED OR DELIVERED DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE US SECURITIES ACT AND IN COMPLIANCE WITH THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION OF THE UNITED STATES. NO PUBLIC OFFERING OF THE SECURITIES REFERRED TO IN THIS ANNOUNCEMENT IS BEING MADE IN THE UNITED STATES, THE UNITED KINGDOM OR ELSEWHERE.

THE CONTENTS OF THIS ANNOUNCEMENT HAVE NOT BEEN REVIEWED BY ANY REGULATORY AUTHORITY IN THE UNITED KINGDOM OR ELSEWHERE. YOU ARE ADVISED TO EXERCISE CAUTION IN RELATION TO THE PLACING. IF YOU ARE IN ANY DOUBT ABOUT ANY OF THE CONTENTS OF THIS ANNOUNCEMENT, YOU SHOULD OBTAIN INDEPENDENT PROFESSIONAL ADVICE.

Neither the Company, Canaccord Genuity Limited ("Canaccord") nor Peel Hunt LLP ("Peel Hunt"), nor any of their respective affiliates, agents, directors, officers, consultants or employees, makes any representation or warranty (whether express or implied) to persons who are invited to and who choose to participate in the placing ("Placees") of new Ordinary Shares (as defined below) in the capital of the Company of nominal value of £0.01 (the "Placing Shares") and of warrants to subscribe for new Ordinary Shares with an exercise price of 9 pence per Ordinary Share (the "Warrants") (the "Placing") regarding an investment in the securities referred to in this Announcement under the laws applicable to such Placees. For every two Placing Shares acquired, each Placee will receive one Warrant (with a package of Placing Shares and Warrants subscribed for being "Units"). Each Placee should consult its own advisers as to the legal, tax, business, financial and related aspects of an investment in the Units.

Certain Directors have indicated an intention to subscribe for new Ordinary Shares (the "Subscription Shares") and Warrants to be issued pursuant to a subscription (the "Subscription").

The Company is also seeking to raise additional funds through an open offer (the "Open Offer"), pursuant to which new Ordinary Shares and Warrants will be offered to existing Shareholders at the Issue Price (as defined below). For the avoidance of doubt, subscription for Units under the Placing will not carry any entitlement to subscribe for new Ordinary Shares or Warrants under the Open Offer.

For the purposes of this Appendix, Canaccord and Peel Hunt are each a "Joint Bookrunner" and together the "Joint Bookrunners".

By participating in the Placing, Placees will be deemed to have read and understood this Announcement, including this Appendix, in its entirety, and to be participating, making an offer and acquiring the Units on the terms and conditions contained herein and to be providing the representations, warranties, indemnities, acknowledgments and undertakings contained herein.

In particular each such Placee represents, warrants, undertakes, agrees and acknowledges that:

1.    it is a Relevant Person and undertakes that it will acquire, hold, manage or dispose of any Units that are allocated to it for the purposes of its business;

2.    it is and, at the time the Units are acquired, will be outside the United States and acquiring the Units in an "offshore transaction" in accordance with Regulation S under the US Securities Act ("Regulation S");

3.    it is acquiring Units for its own account or is acquiring Units for an account with respect to which it exercises sole investment discretion, and not with a view to distribution, and has the authority to make and does make the representations, warranties, indemnities, acknowledgments, undertakings and agreements contained in this Announcement;

4.    if it is a financial intermediary, as that term is used in Article 2(d) of the EU Prospectus Regulation or the UK Prospectus Regulation, as applicable, any Units acquired by it in the Placing will not be acquired on a non-discretionary basis on behalf of, nor will they be acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of securities to the public other than an offer or resale to Qualified Investors in a member state of the EEA or in the UK, as applicable, or in circumstances in which the prior consent of the Joint Bookrunners has been given to each such proposed offer or resale; and

5.    the Company and the Joint Bookrunners  will rely upon the truth and accuracy of and compliance with the foregoing representations, warranties, undertakings, acknowledgements and agreements. Each Placee hereby agrees with the Joint Bookrunners and the Company to be bound by these terms and conditions as being the terms and conditions upon which the Units will be issued. A Placee shall, without limitation, become so bound if either Joint Bookrunner confirms to such Placee its allocation of Units.

The distribution of this Announcement and the Placing and/or the offer or sale of the Placing Shares and/or Warrants in certain jurisdictions may be restricted by law. No action has been taken by the Company or by the Joint Bookrunners or any of its or their respective affiliates or any of its or their respective agents, directors, officers or employees which would, or is intended to, permit an offer of the Placing Shares and/or Warrants or possession or distribution of this Announcement or any other offering or publicity material relating to such Placing Shares and/or Warrants in any country or jurisdiction where any such action for that purpose is required. The information in this Announcement may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, dissemination, reproduction, or disclosure of this information in whole or in part is unauthorised. Failure to comply with this directive may result in a violation of the US Securities Act or the applicable laws of other jurisdictions.

Details of the Placing Agreement

The Company and the Joint Bookrunners have today entered into an agreement with respect to the Placing (the "Placing Agreement") under which, on the terms and subject to the conditions set out therein, the Joint Bookrunners have agreed (severally and not jointly or jointly and severally) to use their respective reasonable endeavours, as agents of the Company, to procure Placees for the Units in such number, if any, as may be agreed between the Joint Bookrunners and the Company and recorded in the executed terms of sale (the "Terms of Sale"). The Joint Bookrunners shall be under no obligation to subscribe or pay for any Units for which they were unable to procure subscribers and/or in respect of which payment is not made by Placees.

Pursuant to the terms of the Placing Agreement, the Placing is subject to certain conditions (including, inter alia, Admission). The issue of the Units is to be effected by way of a cash box placing. In accordance with the Placing Agreement and a subscription and transfer agreement entered into between the Company, Project Elephant Funding Limited (a Jersey incorporated subsidiary of the Company) ("JerseyCo") and Canaccord, the Company will allot and issue the Units on a non pre-emptive basis to Canaccord, as bare nominee for the Placees (pending transfer of legal title to the Placees through CREST), in consideration for the transfer to the Company by Canaccord of certain shares which it holds in JerseyCo. Accordingly, instead of receiving cash as consideration for the issue of the Units, the Company will, conditional on Admission and following the conclusion of the Placing, own all of the issued share capital of JerseyCo, whose only asset will be its cash reserves, which will represent an amount approximately equal to the net proceeds of the Placing. By taking up or purchasing Units under the Placing and submitting a valid payment in respect thereof, a Placee instructs Canaccord and/or Peel Hunt (as applicable) to hold such payment and in the case of Placees procured by Peel Hunt, to the transfer by Peel Hunt of the net Placing proceeds to Canaccord and: (i) to the extent of a successful application under the Placing, to apply such payment on behalf of Canaccord solely for Canaccord to subscribe (as principal) for redeemable preference shares in JerseyCo; and (ii) to the extent of an unsuccessful application under the Placing, Canaccord and/or Peel Hunt to return the relevant payment without interest to the applicant. The Joint Bookrunners also have the right to terminate the Placing Agreement in certain circumstances. Further details of the Placing Agreement are set out below.

The Placing Shares

The Placing Shares have been duly authorised and will, when issued, be credited as fully paid and will rank pari passu in all respects with the existing ordinary shares in the Company, including the right to receive all dividends and other distributions declared, made or paid in respect of the ordinary shares of the Company (the "Ordinary Shares") after the date of issue of the Placing Shares, save that the Placing Shares will not carry an entitlement to participate in the Open Offer.

Applications for admission to trading

Applications will be made for the Placing Shares and the Subscription Shares to be admitted to the London Stock Exchange's AIM market ("Admission"). It is expected that Admission will become effective on or around 8.00 a.m. (London time) on 20 June 2022 (or on such later date as may be agreed between the Company and the Joint Bookrunners) and that dealings in the Placing Shares and Subscription Shares will commence at that time.

Bookbuild        

The Joint Bookrunners will commence with immediate effect a bookbuilding process in relation to the Placing (the "Bookbuild") to establish demand for participation in the Placing by Placees at an issue price of 7 pence per Unit (the "Issue Price"). This Appendix gives details of the terms and conditions of, and the mechanics of participation in, the Placing. No commissions will be paid to Placees or by Placees in respect of any Units.

The Joint Bookrunners and the Company shall be entitled to effect the Placing by such alternative method to the Bookbuild as they may, in their absolute discretion, determine.

Warrants

The Warrants will be issued on the basis of one Warrant per two Placing Shares acquired and will be subject to the terms and conditions of the Warrant Instrument (as defined below). Each Warrant will entitle the registered holder the right to subscribe for new Ordinary Shares at an exercise price of 9 pence per Ordinary Share. The Warrants shall be exercisable from the date of issue of the Warrants up to (and including) 5.00 pm on 31 December 2023. No application will be made for the Warrants to be admitted to trading on AIM. The Warrants will be, subject to certain conditions, freely transferrable by the holder.

The Warrants shall be constituted by a warrant instrument to be executed by the Company prior to Admission (the "Warrant Instrument"). The Warrant Instrument will contain (i) customary provisions adjusting the subscription price and/or number of Warrants for distributions of capital, share splits and share consolidations and (ii) an undertaking from the Company to make an application to the London Stock Exchange for any Ordinary Shares allotted on the exercise of the Warrants to be admitted to trading on AIM.

Participation in, and principal terms of, the Placing

1.         Canaccord and Peel Hunt are acting severally, and not jointly, or jointly and severally, as joint bookrunners and agents of the Company in connection with the Placing.

2.         Participation in the Placing will only be available to Relevant Persons who may lawfully be, and are, invited by the Joint Bookrunners to participate. The Joint Bookrunners and any of their affiliates may, acting as investors for their own account acquire Units in the Placing.

3.         The Placing shall be conducted by way of a bookbuild to establish the number of Units to be allocated to Placees, which will comprise their allocation of Placing Shares and Warrants.

4.         The Bookbuild will commence on the release of this Announcement and will close at a time to be determined by the Joint Bookrunners in their absolute discretion (after consultation with the Company), expected to be no later than 7.00 a.m. (London time) on 16 June 2022. The Joint Bookrunners may, in agreement with the Company, accept bids that are received after the Bookbuild has closed.

5.         The number of Units to be issued will be agreed between the Joint Bookrunners and the Company following completion of the Bookbuild. The number of Units to be issued will be announced by the Company via a Regulatory Information Service ("RIS") following the completion of the Bookbuild (the "Placing Results").

6.         To bid in the Bookbuild, Placees should communicate their bid by telephone and/or in writing to their usual sales contact at Canaccord or Peel Hunt. Each bid should state the number of Units which the prospective Placee wishes to subscribe for at the Issue Price. Bids may also be scaled down by the Joint Bookrunners on the basis referred to in paragraph 10 below.

7.         A bid in the Bookbuild will be made on the terms and subject to the conditions in this Announcement and will be legally binding on the Placee on behalf of which it is made and, except with the consent of the Joint Bookrunners, will not be capable of variation or revocation after the time at which it is submitted.

8.         Each prospective Placee's allocation will be agreed between the Joint Bookrunners and the Company and will be confirmed orally or in writing by one of the Joint Bookrunners (each as agent for the Company) following the close of the Bookbuild and a trade confirmation or contract note will be despatched thereafter. This oral or written confirmation from a Joint Bookrunner to a Placee will constitute an irrevocable legally binding commitment upon that person (who will at that point become a Placee) in favour of Canaccord, Peel Hunt and the Company to subscribe for the number of Units allocated to it at the Issue Price on the terms and conditions set out in this Appendix and in accordance with the Company's articles of association. The terms and conditions of this Announcement will be deemed to be incorporated in that trade confirmation, contract note or such other (oral or written) confirmation and will be legally binding on the Placee on behalf of which it is made. All obligations under the Bookbuild and Placing will be subject to fulfilment of the conditions referred to below under "Conditions of the Placing" and to the Placing not being terminated on the basis referred to below under "Termination of the Placing Agreement".

9.         Each Placee will have an immediate, separate, irrevocable and binding obligation owed to the Joint Bookrunners, as agents for the Company, to pay in cleared funds at the relevant time in accordance with the requirements set out below under "Registration and Settlement", an amount equal to the product of the Issue Price and the number of Units such Placee has agreed to acquire and the Company has agreed to allot.

10.        The Joint Bookrunners may choose to accept bids, either in whole or in part, on the basis of allocations determined by the Company (having consulted with the Joint Bookrunners) and may scale down any bids for this purpose on such basis as the Company may in its absolute discretion determine. The Joint Bookrunners may also, notwithstanding paragraphs 6 and 9 above, (i) allocate Units after the time of any initial allocation to any person submitting a bid after that time; and (ii) allocate Units after the Bookbuild has closed to any person submitting a bid after that time. The Company reserves the right (with the agreement of the Joint Bookrunners) to reduce or seek to increase the amount to be raised pursuant to the Placing, in agreement with the Joint Bookrunners. As noted above, the Company will release an announcement following the close of the Bookbuild, detailing the aggregate number of Units to be issued.

11.        Irrespective of the time at which a Placee's allocation(s) pursuant to the Placing is confirmed, settlement for all Units to be subscribed for pursuant to the Placing will be required to be made at the same time, on the basis explained below under "Registration and Settlement".

12.        Completion of the Placing will be subject to the fulfilment of the conditions referred to below under "Conditions of the Placing" and to the Placing not being terminated on the basis referred to below under "Termination of the Placing Agreement". In the event that the Placing Agreement does not become unconditional in any respect or is terminated, the Placing will not proceed.

13.        By participating in the Placing, each Placee will agree that its rights and obligations in respect of the Placing will terminate only in the circumstances described below and will not be capable of rescission or termination by the Placee, and is not subject to any further conditions or requirements other than those set out in this Announcement or the Placing Agreement.

14.        To the fullest extent permissible by law, neither Canaccord nor Peel Hunt nor any of their respective affiliates, agents, directors, officers, consultants or employees shall have any liability to Placees (or to any other person whether acting on behalf of a Placee or otherwise) in connection with the Placing or the Bookbuild. In particular, none of the Joint Bookrunners nor any of their respective affiliates, agents, directors, officers, consultants or employees shall have any liability (including to the fullest extent permissible by law, any fiduciary duties) in respect of the relevant Joint Bookrunner's conduct of the Bookbuild or of such alternative method of effecting the Placing as the Joint Bookrunners and the Company may agree.

Conditions of the Placing

The Placing is conditional upon, among other things, the Placing Agreement becoming unconditional and not having been terminated in accordance with its terms.

The obligations of the Joint Bookrunners under the Placing Agreement are conditional on, among other things:

(a)        the Joint Bookrunners and the Company entering into the Terms of Sale;

(b)        there having been no breach, in the opinion of either Joint Bookrunner acting in good faith, by the Company or JerseyCo of any of their obligations under the initial subscription and option agreement or the subscription and transfer agreement before Admission;

(c)        the Warrants having been duly constituted by the Company pursuant to the Warrant Instrument and all conditions relating to the issue of the Warrants having been satisfied, save for any condition relating to Admission;

(d)        in the opinion of either Joint Bookrunner, acting in good faith, there having been no material adverse effect or change in, or any development or matter reasonably likely to give rise to or involve a material adverse effect or change, in or affecting,  the condition (financial, operational, legal or otherwise), earnings, business affairs, assets, results of operations or prospects of any member of the Group, whether or not arising in the ordinary course of business and whether or not foreseeable at the date of this Agreement;

(e)        in the opinion of either Joint Bookrunner, acting in good faith, the warranties, undertakings and covenants on the part of the Company contained or referred to in the Placing Agreement being true, accurate and not misleading as at the date of the Placing Agreement, the date of the Terms of Sale, the date of the circular to be published by the Company in connection with the Open Offer and the date of Admission, as though they had been given and made on the relevant date by reference to the facts and circumstances then subsisting; and        

(f)         Admission in respect of the Placing Shares and Subscription Shares taking place by not later than 8.00 a.m. (London time) on 20 June 2022 (or such later time and/or date as the Joint Bookrunners may agree with the Company).

The Joint Bookrunners may, in their absolute discretion and on such terms as each Joint Bookrunner thinks appropriate, waive fulfilment, in whole or in part, of any or all of the conditions in the Placing Agreement by giving notice in writing to the Company. The Company and the Joint Bookrunners may agree in writing to extend the time by which any of the Conditions may be fulfilled. Any such waiver by the Joint Bookrunners will not affect Placees' commitments as set out in this Announcement.

If: (i) any of the conditions contained in the Placing Agreement are not fulfilled or waived by the Joint Bookrunners by the time or date specified (or such later time and/or date as the Company and the Joint Bookrunners may agree); or (ii) any of such conditions become incapable of being fulfilled; or (iii) the Placing Agreement is terminated in the circumstances specified below under "Termination of the Placing Agreement", the Placing will not proceed and the Placees' rights and obligations hereunder in relation to the Units shall cease and terminate at such time and each Placee agrees that no claim can be made by the Placee in respect thereof.

Neither the Company, Canaccord, Peel Hunt, nor any of their respective affiliates, agents, directors, officers, consultants or employees, shall have any liability, whether in contract, tort or otherwise, to any Placee (or to any other person whether acting on behalf of a Placee or otherwise) in respect of any decision they may make as to whether or not to waive or to extend the time and/or the date for the satisfaction of any condition to the Placing nor for any decision they may make as to the satisfaction of any condition or in respect of the Placing generally, and by participating in the Bookbuild and the Placing, each Placee agrees that any such decision is within the absolute discretion of the Joint Bookrunners and the Company. Placees will have no rights against Canaccord, Peel Hunt, the Company or any of their respective members, directors or employees under the Placing Agreement pursuant to the Contracts (Rights of Third Parties) Act 1999 (as amended) or otherwise.

Lock-up

As part of the Placing, the Company has undertaken, subject to certain customary agreed exceptions, that it will not, among other things, directly or indirectly, offer, issue, allot, lend, mortgage, assign, charge, pledge, sell or contract to sell or issue, issue options in respect or otherwise dispose of, directly or indirectly, or announce an offering or issue of any Ordinary Shares (or any interest therein or in respect thereof) or any other securities exchangeable for or convertible into, or substantially similar to, Ordinary Shares or enter into any transaction with the same economic effect as the foregoing in respect of any Ordinary Shares in the period from the date of this Announcement until 120 days after Admission without the prior written consent of the Joint Bookrunners.

By participating in the Placing, Placees agree that the exercise by the Joint Bookrunners of any power to grant consent to waive the undertaking by the Company in respect of a transaction which would otherwise be subject to the lock-up under the Placing Agreement shall be within the absolute discretion of the Joint Bookrunners and that they need not make any reference to, or consult with, Placees and that the Joint Bookrunners shall have no liability to Placees whatsoever in connection with any such exercise of their power to grant such consent.

Termination of the Placing Agreement

The Joint Bookrunners are entitled, at any time prior to Admission, to terminate the Placing Agreement in accordance with its terms by giving notice in writing to the Company in certain circumstances, including in the event of, inter alia: (i) any of the warranties of the Company contained in the Placing Agreement in the opinion of either Joint Bookrunner, acting in good faith, not being or ceasing to be true, accurate or not misleading; (ii) in the opinion of either Joint Bookrunner, acting in good faith, any statement contained in certain documents issued, or entered into, by the Company in connection with the Placing being or becoming untrue or inaccurate in any material respect or is or becomes misleading (or any matter having arisen which would constitute an omission from such documents), in each case which either Joint Bookrunner considers to be material in the context of the Capital Raising, the Placing, the Units, Admission or any other transaction contemplated by the Placing Agreement; (iii) in the opinion of either Joint Bookrunner, acting in good faith, there having been a breach by the Company and/or JerseyCo with any of their obligations under the initial subscription and option agreement or the subscription and transfer agreement; (iv) the application for Admission being withdrawn and/or refused by the London Stock Exchange; (v) the occurrence, in the opinion of either Joint Bookrunner  acting in good faith, of a material adverse effect or change in, or any development or matter reasonably likely to give rise to or involve a material adverse effect or change, in or affecting the condition (financial, operational, legal or otherwise) earnings, business affairs, assets, results of operations or prospects of any member of the Group, whether or not arising in the course of business and whether or not foreseeable at the date of the Placing Agreement; (vi) the occurrence of certain force majeure events which make it, in the judgement of either Joint Bookrunner, acting in good faith, impracticable or inadvisable to market the Ordinary Shares or to enforce contracts for the Subscription and/or sale of the Ordinary Shares; or (vii) the cancellation or suspension by the London Stock Exchange of trading in the Company's securities.

Upon such termination, the Company and the Joint Bookrunners shall be released and discharged (except for any liability arising before or in relation to such termination) from their respective obligations under or pursuant to the Placing Agreement and the Placing will not proceed.

By participating in the Placing, Placees agree that the exercise or non-exercise by either Joint Bookrunner of any right of termination or other discretion under the Placing Agreement shall be within the absolute discretion of each of the Joint Bookrunners and that neither of the Joint Bookrunners need make any reference to the Placees prior to such exercise and that neither of the Joint Bookrunners nor their respective affiliates or their or their respective affiliates' agents, members, directors, officers or employees, respectively, shall have any liability to Placees whatsoever in connection with any such exercise or failure so to exercise.

No prospectus

No offering document or prospectus has been or will be submitted to be approved by the UK Financial Conduct Authority (the "FCA") or any other regulator in relation to the Bookbuild or the Placing and Placees' commitments will be made solely on the basis of the information contained in this Announcement (including this Appendix) which has been released by the Company today and any information publicly announced to a RIS by or on behalf of the Company prior to or on the date of this Announcement and subject to the further terms set forth in the contract note or trade confirmation to be provided to individual prospective Placees.

Each Placee, by accepting a participation in the Bookbuild and the Placing, agrees that the content of this Announcement (including this Appendix) is exclusively the responsibility of the Company and confirms that it has neither received nor relied on any other information, representation, warranty, or statement made by or on behalf of the Company, or the Joint Bookrunners other than publicly available information and neither of the Joint Bookrunners or the Company nor any person acting on their behalf nor any of their respective affiliates has or shall have any liability for any Placee's decision to participate in the Bookbuild and the Placing based on any other information, representation, warranty or statement which the Placees may have obtained or received. Each Placee acknowledges and agrees that it has relied on its own investigation of the business, financial or other position of the Company in accepting a participation in the Placing. Nothing in this paragraph shall exclude or limit the liability of any person for fraudulent misrepresentation by that person.

Registration and settlement

Settlement of transactions in the Placing Shares following Admission of the Placing Shares and Subscription Shares will take place within the systems administered by Euroclear UK & International Limited ("CREST"). Settlement of the Placing Shares will be on a delivery versus payment basis. The Warrants will also be capable of being settled in CREST and it is currently intended that settlement of Warrants via CREST will be on the same timetable as settlement of the Placing Shares and Subscription Shares. Each Placee should provide its settlement details in order to enable instructions to be successfully matched in CREST and the Warrants settled on a free of payment basis. Subject to certain exceptions, the Joint Bookrunners and the Company reserve the right to require settlement and delivery of the Units (or a portion thereof) to Placees by such other means that it deems necessary or in certificated form if delivery or settlement is not possible or practicable within the CREST system or would not be consistent with the regulatory requirements in the relevant Placee's jurisdiction.

Following the close of the Bookbuild, each Placee allocated Units in the Placing will be sent a contract note or trade confirmation stating the number of Units to be allocated to it at the Issue Price, the aggregate amount owed by such Placee to Canaccord or Peel Hunt as appropriate and settlement instructions. Each Placee agrees that it will do all things necessary to ensure that delivery and payment is completed in accordance with either the standing CREST or certificated settlement instructions, as appropriate, that it has in place with the relevant Joint Bookrunner.

The Company will deliver the Units taken up by Placees to CREST account(s) operated by the Joint Bookrunners. The input to CREST by a Placee of a matching or acceptance instruction will then allow delivery of the relevant Units to that Placee against payment.

It is expected that settlement through CREST will be from 8:00 a.m. (London time) on 20 June 2022 on a delivery versus payment basis in accordance with the instructions set out in the trade confirmation unless otherwise notified by Canaccord or Peel Hunt. Interest is chargeable daily on payments not received from Placees on the due date in accordance with the arrangements set out above, in respect of either CREST or certificated deliveries.

The Warrants will not be listed or admitted to trading on AIM or any other stock exchange.

Each Placee is deemed to agree that, if it does not comply with these obligations, Canaccord or Peel Hunt may sell any or all of the Units allocated to that Placee on such Placee's behalf and retain from the proceeds, for its own account and benefit (as agent for the Company), an amount equal to the aggregate amount owed by the Placee plus any interest due. The relevant Placee will, however, remain liable for and shall indemnify the relevant Joint Bookrunner on demand for any shortfall below the aggregate amount owed by it for the Units and for any stamp duty or stamp duty reserve tax and any other similar or equivalent duties or taxes (together with any interest or penalties) which may arise upon the sale of such Units on such Placee's behalf. Each Placee confers on the Joint Bookrunners all such authorities and powers necessary to carry out any such sale and agrees to ratify and confirm all actions which either of the Joint Bookrunners lawfully undertakes in pursuance of such sale. Legal and/or beneficial title in and to any Units shall not pass to the relevant Placee until it has fully complied with its obligations hereunder.

If any of the Units are to be delivered to a custodian or settlement agent, Placees should ensure that the contract note is copied and delivered immediately to the relevant person within that organisation. Insofar as any of the Units are registered in a Placee's name or that of its nominee or in the name of any person for whom a Placee is contracting as agent or that of a nominee for such person, such Units should, subject as provided below, be so registered free from any liability to UK stamp duty or stamp duty reserve tax. Placees shall not be entitled to receive any fee or commission in connection with the Bookbuild or the Placing. If there are any circumstances in which any other stamp duty or stamp duty reserve tax (together with interest and penalties) is payable in respect of the issue of the Units, none of the Joint Bookrunners or the Company shall be responsible for the payment thereof.

Representations and warranties

By participating in the Placing each Placee (and any person acting on such Placee's behalf) irrevocably represents, warrants, undertakes, acknowledges, confirms and agrees with the Company and each of the Joint Bookrunners, in each case as a fundamental term of its participation, that:

1.         its commitment is made solely on the basis of publicly available information and subject to this Appendix and not on the basis of any other information given, or any representation or statement made at any time, by any person concerning the Company, the Units or the Placing. It agrees that neither the Company nor the Joint Bookrunners, or any of their respective officers, agents, employees or affiliates will have any liability for any other information or representation. It irrevocably and unconditionally waives any rights it may have in respect of any other information or representation;

2.         it has carefully read and understands this Announcement, including this Appendix, in its entirety and acknowledges that its acquisition of Units is subject to and based upon all the terms, conditions, representations, warranties, acknowledgements, agreements and undertakings and other information contained in this Announcement and not in reliance on any information, representation, warranties or statements other than those contained in the Announcement. It further agrees that these terms and conditions represent the whole and only agreement between each Placee, the Company and the Joint Bookrunners in relation to each Placee's participation in the Placing and supersede any previous agreement between any of such parties in relation to such participation. Accordingly, all other terms, conditions, representations, warranties and other statements which would otherwise be implied (by law or otherwise) shall not form part of these terms and conditions. It agrees that neither of the Company or the Joint Bookrunners, nor any of their respective officers or directors, will have any liability for any such other information or representation and irrevocably and unconditionally waives any rights it may have in respect of any such other information or representation;

3.         it has not relied on any information, representations, warranties or statements other than those contained in this Announcement, and undertakes not to redistribute or duplicate this Announcement;

4.         it has not relied on either of the Joint Bookrunners or any person affiliated with either of them in connection with any investigation of the accuracy of any information contained in this Announcement;

5.         it acknowledges that no offering document or prospectus has been or will be prepared in connection with the Bookbuild, Placing or the Units to be issued pursuant to the Placing and it has not received and will not receive a prospectus or other offering document in connection with the Bookbuild, the Placing or the Units to be issued pursuant to the Placing;

6.         it acknowledges that none of the Joint Bookrunners, the Company nor any of their respective affiliates, agents, directors, officers, consultants or employees nor any person acting on behalf of any of them has provided, and none of them will provide, it with any material or information regarding the Units or the Company or any other person other than this Announcement, including this Appendix, nor has it requested either of the Joint Bookrunners, the Company, nor any of their respective affiliates or any person acting on behalf of any of them to provide it with any such material or information;

7.         unless otherwise specifically agreed with the Joint Bookrunners, it is not, and at the time the Units are acquired, neither it nor the beneficial owner of the Units will be a resident of the United States, Canada, Australia, South Africa, Japan, New Zealand, or a citizen, resident or national of any other state or jurisdiction in which it is unlawful to make or accept an offer to acquire the Units (each a "Restricted Territory") and further acknowledges that neither the Units, nor the Placing Shares nor Warrants have been nor will be registered under the securities legislation of the United States or any other Restricted Territory and, subject to certain exceptions, may not be offered, sold, transferred, delivered or distributed, directly or indirectly, in or into those jurisdictions;

8.         it has not, directly or indirectly, distributed, forwarded, transferred or otherwise transmitted this Announcement or any other offering materials concerning the Placing or the Units to any persons within a Restricted Territory or any other jurisdiction in which it would be unlawful to do so, nor will it do any of the foregoing;

9.         it is not acting on a non-discretionary basis for the account or benefit of any person located within the United States or any other Restricted Territory at the time the undertaking to subscribe for the Units was given and it is not acquiring the Units, the Placing Shares or Warrants with a view to the offer, sale, resale, transfer, delivery or distribution, directly or indirectly, of any Units, the Placing Shares or Warrants into the United States or any other Restricted Territory; 

10.        it acknowledges that the content of this Announcement is exclusively the responsibility of the Company and its Directors and that neither of the Joint Bookrunners nor any of their respective affiliates, agents, directors, officers, consultants or employees nor any person acting on their behalf are responsible for or shall have any liability, in contract, tort or otherwise for any information, representation or statement contained in this Announcement, any misstatements in or omission from any publicly available information relating to the Company, or any information previously or subsequently published by or on behalf of the Company, including, without limitation, any information required to be published by the Company pursuant to applicable laws (the "Exchange Information") and will not be liable for any Placee's decision to participate in the Placing based on any information, representation or statement contained in this Announcement or any information published prior to or on the date of this Announcement by or on behalf of the Company or otherwise. It further represents, warrants and agrees that the only information on which it is entitled to rely and on which it has relied in committing itself to subscribe for the Units is contained in this Announcement and any information previously published by the Company by notification to a RIS, such information being all that it deems necessary to make an investment decision in respect of the Units and that it has neither received nor relied on any other information given or representations, warranties or statements made by the Joint Bookrunners or the Company and neither the Joint Bookrunners nor the Company will be liable for any Placee's decision to accept an invitation to participate in the Placing based on any other information, representation, warranty or statement. It further acknowledges and agrees that it has conducted and relied on its own investigation of the business, financial or other position of the Company in deciding to participate in the Placing and has received and reviewed all information that it believes is necessary or appropriate in connection with its purchase of the Units and has made its own assessment and has satisfied itself concerning the relevant tax, legal, regulatory, currency and other economic considerations relevant to its investment in the Units. Neither the Joint Bookrunners, the Company nor any of their respective affiliates has made any representations to it, express or implied, with respect to the Company, the Placing, the Units or the accuracy, completeness or adequacy of the Exchange Information, and each of them expressly disclaims any liability in respect thereof. Nothing in this paragraph or otherwise in this Announcement excludes the liability of any person for fraudulent misrepresentation made by that person;

11.        it acknowledges that the issue to it, or the person specified by it for registration as holder, of the Units will not give rise to a liability under any of sections 67, 70, 93 or 96 of the Finance Act 1986 (depositary receipts and clearance services) and that the Units are not being acquired in connection with arrangements to issue depositary receipts or to issue or transfer Units into a clearance service;

12.        it is not applying as, nor is it applying as nominee or agent for, a person who is or may be liable to notify and account for tax under the Stamp Duty Reserve Tax Regulations 1986 or equivalent legislation or regulation;

13.        it has complied with its obligations under the Criminal Justice Act 1993 (the "CJA"), the Market Abuse Regulation (EU) No.596/2014 ("EU MAR"), EU MAR as amended and transposed into the laws of the United Kingdom pursuant to the European Union (Withdrawal) Act 2018 and the European Union (Withdrawal Agreement) Act 2020 ("UK MAR"), and in connection with money laundering and terrorist financing under the Proceeds of Crime Act 2002 (as amended), the Terrorism Act 2000 (as amended), the Anti-Terrorism Crime and Security Act 2001, the Terrorism Act 2006, the Money Laundering, Terrorist Financing and Transfer of Funds (Information on the Payer) Regulations 2017 and any applicable related or similar rules, regulations or guidelines, issued, administered or enforced by any government agency having jurisdiction in respect of the prevent of money laundering and the Money Laundering Sourcebook of the FCA (the "Regulations") and, if making payment on behalf of a third party, that satisfactory evidence has been obtained and recorded by it to verify the identity of the third party as required by the Regulations, and its application is only made on the basis that it accepts full responsibility for any requirement to verify the identity of its clients and other persons in respect of whom it has applied and recorded by it to verify the identity of the third party as required by the applicable law;

14.        it acknowledges that due to anti-money laundering requirements and the countering of terrorist financing, the Joint Bookrunners and the Company may require proof of identity and verification of the source of the payment before the application can be processed and that, in the event of delay or failure by the applicant to produce any information required for verification purposes, the Joint Bookrunners and the Company may refuse to accept the application and the subscription monies relating thereto. It holds harmless and will indemnify the Joint Bookrunners and the Company against any liability, loss or cost ensuing due to the failure to process such application, if such information as has been requested has not been provided by it in a timely manner;

15.        it is acting as principal only in respect of the Placing or, if it is acting for any other person: (i) it is duly authorised to do so and has full power to make the acknowledgments, representations and agreements herein on behalf of each such person; (ii) it exercises sole investment discretion as to each such person's account; and (iii) it is and will remain liable to the Joint Bookrunners and the Company for the performance of all its obligations as a Placee in respect of the Placing (regardless of the fact that it is acting for another person);

16.        it is acting as principal only in respect of the Placing, or, if it is acting for any other person: (i) it is duly authorised to do so and has full power to make the acknowledgments, representations and agreements herein on behalf of each such person; (ii) it exercises sole investment discretion as to each such person's account; (iii) it is and will remain liable to the Joint Bookrunners and the Company for the performance of all its obligations as a Placee in respect of the Placing (regardless of the fact that it is acting for another person);

17.        it is a Relevant Person and undertakes that it will acquire, hold, manage or dispose of any Units that are allocated to it for the purposes of its business;

18.        it understands that any investment or investment activity to which this Announcement relates is available only to Relevant Persons and will be engaged in only with Relevant Persons, and further understands that this Announcement must not be acted on or relied on by persons who are not Relevant Persons;

19.        if in a member state of the EEA, unless otherwise specifically agreed with the Joint Bookrunners and the Company in writing, it is an EU Qualified Investor and, to the extent applicable, any funds on behalf of which it is acquiring the Units that are located in a member state of the EEA are each such an EU Qualified Investor;

20.        if it is a financial intermediary, as that term is used in Article 2(d) of the EU Prospectus Regulation or UK Prospectus Regulation, as applicable, any Units subscribed for by it in the Placing will not be subscribed for on a non-discretionary basis on behalf of, nor will they be acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of securities to the public other than an offer or resale to Qualified Investors in a member state of the EEA or in the UK, as applicable, or in circumstances in which the prior consent of the Joint Bookrunners has been given to the proposed offer or resale;

21.        it acknowledges that any offer of Units may only be directed at persons in member states of the EEA and the United Kingdom who are Qualified Investors and it represents, warrants and undertakes that it has not offered or sold and will not offer or sell any Units to any persons in a member state of the EEA or the United Kingdom prior to Admission except to Qualified Investors or otherwise in circumstances which will not result in an offer to the public in any member state of the EEA or the United Kingdom within the meaning of the EU Prospectus Regulation or the UK Prospectus Regulation, as applicable;

22.        neither this Announcement nor any other offering, marketing or other material in connection with the Placing constitutes an invitation, offer or promotion to, or arrangement with, it or any person whom it is procuring to subscribe for Units pursuant to the Placing unless, in the relevant territory, such offer, invitation or other course of conduct could lawfully be made to it or such person and such documents or materials could lawfully be provided to it or such person and the Units could lawfully be distributed to and subscribed and held by it or such person without compliance with any unfulfilled approval, registration or other regulatory or legal requirements;

23.        it has not offered or sold and, prior to the expiry of a period of six months from Admission, will not offer or sell any Units to persons in the United Kingdom, except to persons whose ordinary activities involve them acquiring, holding, managing or disposing of investments (as principal or agent) for the purposes of their business or otherwise in circumstances which have not resulted in, and which will not result in, an offer to the public in the United Kingdom within the meaning of section 85(1) of the Financial Services and Markets Act 2000 ("FSMA");

24.        it has not offered or sold and will not offer or sell any Units to persons in the EEA prior to Admission except to persons whose ordinary activities involve them acquiring, holding, managing or disposing of investments (as principal or agent) for the purposes of their business or otherwise in circumstances which have not resulted in, and which will not result in an offer to the public in any member state of the EEA within the meaning of the EU Prospectus Regulation and will not result in a requirement for the publication of a prospectus pursuant to Article 3 of the EU Prospectus Regulation;

25.        it has only communicated or caused to be communicated and will only communicate or cause to be communicated any invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) relating to the Units in circumstances in which section 21(1) of FSMA does not require approval of the communication by an authorised person;

26.        it has complied and will comply with all applicable provisions of FSMA with respect to anything done by it in relation to the Placing in, from or otherwise involving, the United Kingdom;

27.        if it is a natural person, it is not under the age of majority (18 years of age in the United Kingdom) on the date of its agreement to subscribe for the Units under the Placing and will not be any such person on the date any such Placing (as applicable) is accepted;

28.        if it is within the United Kingdom, it is a person (i) having professional experience in matters relating to investments who falls within the definition of "investment professionals" in Article 19(5) of the Order, (ii) who falls within Article 49(2)(a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and in either case of (i) or (ii) who also constitutes a UK Qualified Investor, or (iii) to whom this Announcement may otherwise lawfully be communicated or, if it is receiving the offer in circumstances under which the laws or regulations of a jurisdiction other than the United Kingdom would apply, that it is a person to whom the Units may be lawfully offered under that other jurisdiction's laws and regulations and is capable of being categorised as a person who is a "professional client" or an "eligible counterparty" within the meaning of chapter 3 of the FCA's Conduct of Business Sourcebook;

29.        it and any person acting on its behalf has capacity and authority and is otherwise entitled to acquire the Units under the laws of all relevant jurisdictions which apply to it and that it has fully observed such laws and obtained all such governmental and other guarantees, permits, authorisations, approvals and consents which may be required thereunder and complied with all necessary formalities and paid any issue, transfer or other taxes due in connection with its application in any territory for, and acceptance in any jurisdiction of, the Units and that it has not taken any action or omitted to take any action which will or may result in the Company, the Joint Bookrunners or the Company's registrar (the "Registrar") or any of their respective directors, officers, agents, employees or advisers acting in breach of the legal or regulatory requirements, directly or indirectly, of any territory or jurisdiction in connection with the Placing and that the subscription for and purchase of the Units by it or any person acting on its behalf will be in compliance with applicable laws and regulations in the jurisdiction of its residence, the residence of the Company, or otherwise;

30.        it and any person acting on its behalf is entitled to acquire the Units under the laws of all relevant jurisdictions and has all necessary capacity and has obtained all necessary consents and authorities to enable it to commit to its participation in the Placing and to perform its obligations in relation thereto (including, without limitation, in the case of any person on whose behalf it is acting, all necessary consents and authorities to agree to the terms set out or referred to in this Announcement) and will honour such obligations;

31.        it and any person acting on its behalf will make payment for the Units allocated to it in accordance with this Announcement on the due time and date set out herein;

32.        it accepts that the allocation of Units shall be determined by the Company (in consultation with the Joint Bookrunners) and that allocation (if any) of Units will represent a maximum number of Units which it will be entitled, and required, to subscribe for, and that the Joint Bookrunners may call upon it to subscribe for a lower number of Units, but in no event in aggregate more than the aforementioned maximum;

33.        that the person whom it specifies for registration as holder of the Units will be (i) itself; (ii) its nominee, as the case may be; or (iii) a person for whom it is contracting as agent or nominee. None of the Joint Bookrunners, the Company, any of their respective affiliates or any person acting on behalf of any of them will be responsible for any liability to stamp duty or stamp duty reserve tax or other similar duties or taxes resulting from a failure to observe this requirement. Each Placee and any person acting on behalf of such Placee agrees to indemnify the Joint Bookrunners and the Company in respect of the same (together with any and all costs, losses, claims, liabilities, penalties, interest, fines and expenses (including legal fees and expenses)) on an after-tax basis on the basis that the Units will be allotted to the CREST stock account of Canaccord or Peel Hunt, as appropriate, who will hold them as nominee on behalf of such Placee until settlement in accordance with its standing settlement instructions;

34.        it acknowledges that neither of the Joint Bookrunners, nor any of their respective affiliates, nor any person acting on its or their behalf, is making any recommendations to it or, advising it regarding the suitability of any transactions it may enter into in connection with the Placing or providing advice in relation to the Placing and that participation in the Placing is on the basis that it is not and will not be a client of either Joint Bookrunner and neither of the Joint Bookrunners has any duties or responsibilities to it for providing the protections afforded to their respective clients or customers or for providing advice in relation to the Placing nor in respect of any representations, warranties, undertakings or indemnities contained in the Placing Agreement nor for the exercise or performance of any of its rights and obligations thereunder including any rights to waive or vary any conditions or exercise any termination right;

35.        in making any decision to subscribe for the Units, it has knowledge and experience in financial, business and international investment matters as is required to evaluate the merits and risks of subscribing for or purchasing the Units. It further confirms that it is experienced in investing in securities of this nature in this sector and is aware that it may be required to bear, and is able to bear, the economic risk of participating in, and is able to sustain a complete loss in connection with, the Placing. It further confirms that it relied on its own examination and due diligence of the Company and its associates taken as a whole, and the terms of the Placing, including the merits and risks involved, and not upon any view expressed or information provided by or on behalf of the Joint Bookrunners. It further confirms that it has had sufficient time to consider and conduct its own investigation with respect to the offer and purchase of the Units, including the legal, regulatory, tax, business, currency and other economic and financial considerations relevant to such investment and it will not look to the Company, either of the Joint Bookrunners, any of their respective affiliates or any person acting on their behalf for all or part of any such loss or losses it or they may suffer;

36.        it acknowledges that it may not rely on any investigation that either of the Joint Bookrunners or any person acting on its behalf may or may not have conducted with respect to the Company and its affiliates or the Placing and the Joint Bookrunners have not made any representation or warranty to it, express or implied, with respect to the merits of the Placing, the subscription for or purchase of the Units, or as to the condition, financial or otherwise, of the Company and its affiliates, or as to any other matter relating thereto, and nothing herein shall be construed as a recommendation to it to subscribe for the Units. It acknowledges, understands and agrees that no information has been prepared or verified by, or is the responsibility of, the Joint Bookrunners for the purposes of this Placing;

37.        it acknowledges that, in connection with the Placing, the Joint Bookrunners and any of their respective affiliates acting as an investor for its own account may take up Units in the Company and in that capacity may retain, purchase or sell for its own account such Units in the Company and any securities of the Company or related investments and may offer or sell such securities or other investments otherwise than in connection with the Placing. The Joint Bookrunners do not intend to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligation to do so;

38.        it acknowledges that the Joint Bookrunners, the Company and their respective affiliates and others will rely upon the truth and accuracy of the representations, warranties and acknowledgements set forth herein and which are given to the Joint Bookrunners on their own behalf and to the Company on its own behalf and are irrevocable and it agrees that if any of the representations or warranties made or deemed to have been made by its subscription of the Units are no longer accurate, it shall promptly notify the Joint Bookrunners and the Company. It irrevocably authorises the Joint Bookrunners and the Company to produce this Announcement, pursuant to, in connection with, or as may be required by any applicable law or regulation, administrative or legal proceeding or official inquiry with respect to the matters set forth herein;

39.        the exercise or non-exercise by the Joint Bookrunners of any right of termination or other discretion under the Placing Agreement shall be within the absolute discretion of the Joint Bookrunners and the Joint Bookrunners need not make any reference to Placees and it accepts that if the Placing does not proceed or the relevant conditions to the Placing Agreement are not satisfied for any reason whatsoever, then neither the Company nor the Joint Bookrunners, nor any persons controlling, controlled by or under common control with any of them nor any of their respective employees, agents, officers, members, stockholders, partners or representatives, shall have any liability to whatsoever to it or any other person;

40.        it will indemnify on an after-tax basis and hold the Joint Bookrunners, the Company and their respective affiliates harmless from any and all costs, claims, liabilities and expenses (including legal fees and expenses) arising out of or in connection with any breach of the representations, warranties, acknowledgements, agreements and undertakings in this Appendix and further agrees that the provisions of this Appendix shall survive after completion of the Placing;

41.        its commitment to subscribe for Units on the terms set out in this Appendix and in the contract note or trade confirmation will continue notwithstanding any amendment that may in future be made to the terms of the Placing and that Placees will have no right to be consulted or require that their consent be obtained with respect to the Placing;

42.        it acknowledges that where it is subscribing for the Units as a fiduciary or agent for one or more discretionary, advisory or investor accounts, that it is authorised in writing for each such account: (i) to subscribe for the Units; (ii) to make, and does make, the foregoing representations, warranties, acknowledgements, agreements and undertakings on such account's behalf; and (iii) to receive on behalf of each such account any documentation relating to the Placing (as applicable) in the form provided by the Company and/or the Joint Bookrunners. It agrees that the provisions of this paragraph shall survive any resale of the Units by or on behalf of any such account;

43.        it acknowledges and agrees that information provided by it to the Company or the Registrar may be stored on the Registrar's computer system and in hard copy. It acknowledges and agrees that for the purposes of applicable data protection legislation and regulations ("Data Protection Law"), the Registrar is required to specify the purposes for which it may hold personal data. The Registrar will only use such information for the purposes set out below (collectively, the "Purposes"), being to:

a)         process a Placee's personal data (including sensitive personal data) as required by or in connection with its holding of Units, including processing personal data in connection with credit and money laundering checks on it;

b)         communicate with a relevant Placee as necessary in connection with its affairs and generally in connection with its holding of Units;

c)         provide personal data to such third parties as the Registrar may consider necessary in connection with its affairs and generally in connection with a relevant Placee's holding of Units or as the Data Protection Law may require, including to third parties outside the United Kingdom or the EEA; and

d)         without limitation, provide such personal data to the Company, the Joint Bookrunners and their respective associates for processing, notwithstanding that any such party may be outside the United Kingdom or the EEA;

44.        in providing the Company and the Registrar with information, it hereby represents and warrants to the Company and the Registrar that it has obtained the consent of any data subjects to the Company and the Registrar and its associates holding and using their personal data for the Purposes (including the explicit consent of the data subjects for the processing of any sensitive personal data for the purpose set out in paragraph 43(a) above);

45.        time is of the essence as regards its obligations under this Appendix, including to settle payment for the Units;

46.        it acknowledges that any document that is to be sent to it in connection with the Placing will be sent at its own risk and may be sent to it at any address provided by it to the Joint Bookrunners; and

47.        it, and any account for which it is acting, is located outside the United States and acquiring the Units in an "offshore transaction", as defined in Regulation S, conducted in accordance with Regulation S and that the Units were not offered to it by means of "directed selling efforts", as defined in Regulation S.

The foregoing representations, warranties and confirmations are given for the benefit of the Company and the Joint Bookrunners and are irrevocable. Each Placee and any person acting on behalf of the Placee acknowledges that neither the Company nor either of the Joint Bookrunners owes any fiduciary or other duties to any Placee in respect of any representations, warranties, undertakings or indemnities in the Placing Agreement.

Miscellaneous

The rights and remedies of the Joint Bookrunners, the Registrar and the Company under these terms and conditions are in addition to any rights and remedies which would otherwise be available to each of them and the exercise or partial exercise of one will not prevent the exercise of others.

Each Placee and any person acting on behalf of each Placee acknowledges and agrees that a Joint Bookrunner or any of its affiliates may, at its absolute discretion, agree to become a Placee in respect of some or all of the Units.

Each Placee and any person acting on behalf of the Placee acknowledges and agrees that it has neither received nor relied on any 'inside information' (for the purposes of EU MAR, UK MAR and section 56 of the CJA) concerning the Company in accepting this invitation to participate in the Placing.

All references to time in this Announcement are to London time unless otherwise stated. All times and dates in this Announcement may be subject to amendment by the Joint Bookrunners (in their absolute discretion). The Joint Bookrunners shall notify the Placees and any person acting on behalf of the Placees of any changes.

In this Announcement, "after-tax basis" means in relation to any payment made to the Company, the Joint Bookrunners or their respective affiliates, agents, directors, officers and employees pursuant to this Announcement where the payment (or any part thereof) is chargeable to any tax, a basis such that the amount so payable shall be increased so as to ensure that after taking into account any tax chargeable (or which would be chargeable but for the availability of any relief unrelated to the loss, damage, cost, charge, expense or liability against which the indemnity is given on such amount (including on the increased amount)) there shall remain a sum equal to the amount that would otherwise have been so payable.

The price of an Ordinary Share and any income expected from them may go down as well as up and investors may not get back the full amount invested upon disposal of the shares. Past performance is no guide to future performance and persons needing advice should consult an independent financial adviser.

In the case of a joint agreement to subscribe for Units under the Placing, references to a Placee in these terms and conditions are to each of the Placees who are a party to that joint agreement and their liability is joint and several.

Each Placee agrees that these terms and conditions and any agreements entered into by it pursuant to these terms and conditions, and any non-contractual obligations arising out of or in connection with such agreements, shall be governed by and construed in accordance with the laws of England and Wales. For the exclusive benefit of the Joint Bookrunners, the Company and the Registrar, each Placee irrevocably submits (on behalf of itself and on behalf of any person on whose behalf it is acting) to the exclusive jurisdiction of the English courts as regards any claim, dispute or matter arising out of any such contract and waives any objection to proceedings in any such court on the ground of venue or on the ground that proceedings have been brought in an inconvenient forum. Enforcement proceedings in respect of the obligation to make payment for the Units (together with any interest chargeable thereon) may be taken by the Joint Bookrunners or the Company in any jurisdiction in which the relevant Placee is incorporated or in which any of its securities have a quotation on a recognised stock exchange.

The Joint Bookrunners and the Company expressly reserve the right to modify the Placing (including, without limitation, its timetable and settlement) at any time before allocations are determined. The Placing is subject to the satisfaction of the conditions contained in the Placing Agreement and the Placing Agreement not having been terminated.

This Announcement has been issued by, and is the sole responsibility, of the Company. No representation or warranty express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by the Joint Bookrunners or by any of their respective affiliates or agents as to or in relation to, the accuracy or completeness of this Announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefore is expressly disclaimed.